Drug intelligence / Profile preview

RO5303253

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO5303253 is a small molecule drug developed by F. Hoffmann-La Roche Ltd. It functions as an inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, a key enzyme required for viral replication. The compound was investigated primarily for the treatment of chronic hepatitis C genotype 1 infection. Clinical development included Phase 1 studies assessing safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with chronic hepatitis C genotype 1. There are no records of regulatory approval or further clinical advancement beyond early-phase trials[1][2][4].

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on RO5303253.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5303253.

Explore the full profile